HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burke, J. M. Articles by Wetzler, L. M. Search for Related Content PubMed PubMed Citation Articles by Burke, J. M. Articles by Wetzler, L. M. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Medline Plus Health Information Eosinophilic Disorders Immunization

Neisseria meningitidis PorB, a TLR2 Ligand, Induces an Antigen-Specific Eosinophil Recall Response: Potential Adjuvant for Helminth Vaccines?¹

Jennifer M. Burke^*,, Lisa M. Ganley-Leal, Asma Khatri and Lee M. Wetzler^2,

^* Department of Pathology, Boston University School of Medicine, and Division of Infectious Diseases, Department of Medicine, Evans Biomedical Research Center, Boston University School of Medicine, Boston Medical Center, Boston, MA 02118

Efficacious adjuvants are important components of new vaccines. The neisserial outer membrane protein, PorB, is a TLR2 ligand with unique adjuvant activity. We demonstrate that PorB promotes Th2-skewed cellular immune response to the model Ag, OVA, in mice, including Ag-specific recall eosinophil recruitment to the peritoneum. PorB induces chemokine secretion by myeloid cells using both TLR2-dependent and -independent mechanisms, suggesting that anatomical distribution of TLR2⁺ cells may not be a limiting factor for potential vaccine strategies. The results from this study suggest that PorB, and other TLR2 ligands, may be ideal for use against pathogens where eosinophilia may be protective, such as parasitic helminths.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by National Institutes of Health Grants AI49388 as well as T32 AI52070 (to L.M.G.-L.).

² Address correspondence and reprint requests to Dr. Lee M. Wetzler, Boston Medical Center, Section of Infectious Disease, 650 Albany Street, Boston, MA 02118. E-mail: lwetzler{at}bu.edu

³ Abbreviations used in this paper: ODN, oligodeoxynucleotide; DC, dendritic cell; OMP, outer membrane protein; HIB, Haemophilus influenzae type B; LOS, lipooligosaccharide; WT, wild type; KO, knockout; PEC, peritoneal exudate cell; PMN, polymorphonuclear neutrophil; FSC/SSC, forward/side scatter; PGN, peptidoglycan; Myo, myoglobin; BMMC, bone marrow-derived mast cell; MALP-2, macrophage activating lipopeptide-2; int, intermediate.

This article has been cited by other articles:

				O. Koeberling, S. Giuntini, A. Seubert, and D. M. Granoff Meningococcal Outer Membrane Vesicle Vaccines Derived from Mutant Strains Engineered To Express Factor H Binding Proteins from Antigenic Variant Groups 1 and 2 Clin. Vaccine Immunol., February 1, 2009; 16(2): 156 - 162. [Abstract] [Full Text] [PDF]

				D. Chiavolini, S. Weir, J. R. Murphy, and L. M. Wetzler Neisseria meningitidis PorB, a Toll-Like Receptor 2 Ligand, Improves the Capacity of Francisella tularensis Lipopolysaccharide To Protect Mice against Experimental Tularemia Clin. Vaccine Immunol., September 1, 2008; 15(9): 1322 - 1329. [Abstract] [Full Text] [PDF]